Literature DB >> 10746558

A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals.

C Bombieri1, S Giorgi, S Carles, R de Cid, F Belpinati, C Tandoi, N Pallares-Ruiz, C Lazaro, B M Ciminelli, M C Romey, T Casals, F Pompei, G Gandini, M Claustres, X Estivill, P F Pignatti, G Modiano.   

Abstract

Given q as the global frequency of the alleles causing a disease, any allele with a frequency higher than q minus the cumulative frequency of the previously known disease-causing mutations (threshold) cannot be the cause of that disease. This principle was applied to the analysis of cystic fibrosis transmembrane conductance regulator (CFTR) mutations in order to decide whether they are the cause of cystic fibrosis. A total of 191 DNA samples from random individuals from Italy, France, and Spain were investigated by DGGE (denaturing gradient gel electrophoresis) analysis of all the coding and proximal non-coding regions of the gene. The mutations detected by DGGE were identified by sequencing. The sample size was sufficient to select essentially all mutations with a frequency of at least 0.01. A total of 46 mutations was detected, 20 of which were missense mutations. Four new mutations were identified: 1341+28 C/T, 2082 C/T, L1096R, and I11131V. Thirteen mutations (125 G/C, 875+40 A/G, TTGAn, IVS8-6 5T, IVS8-6 9T, 1525-61 A/G, M470V, 2694 T/G, 3061-65 C/A, 4002 A/G, 4521 G/A, IVS8 TG10, IVS8 TG12) were classified as non-CF-causing alleles on the basis of their frequency. The remaining mutations have a cumulative frequency far exceeding q; therefore, most of them cannot be CF-causing mutations. This is the first random survey capable of detecting all the polymorphisms of the coding sequence of a gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746558     DOI: 10.1007/s004390051025

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  9 in total

1.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

2.  Complete gene scanning by temperature gradient capillary electrophoresis using the cystic fibrosis transmembrane conductance regulator gene as a model.

Authors:  Lan-Szu Chou; Friederike Gedge; Elaine Lyon
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

3.  The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis.

Authors:  Michele D Bishop; Steven D Freedman; Julian Zielenski; Najma Ahmed; Annie Dupuis; Sheelagh Martin; Lynda Ellis; Julie Shea; Isobel Hopper; Mary Corey; Paul Kortan; Gregory Haber; Christine Ross; John Tzountzouris; Leslie Steele; Peter N Ray; Lap-Chee Tsui; Peter R Durie
Journal:  Hum Genet       Date:  2005-09-29       Impact factor: 4.132

4.  Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls.

Authors:  F U Weiss; P Simon; N Bogdanova; J Mayerle; B Dworniczak; J Horst; M M Lerch
Journal:  Gut       Date:  2005-06-29       Impact factor: 23.059

5.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.

Authors:  Michael Wilschanski; Annie Dupuis; Lynda Ellis; Keith Jarvi; Julian Zielenski; Elizabeth Tullis; Sheelagh Martin; Mary Corey; Lap-Chee Tsui; Peter Durie
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

Review 6.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

7.  Analysis of CFTR Gene Variants in Idiopathic Bronchiectasis in Serbian Children.

Authors:  Katarina Milosevic; Aleksandra Nikolic; Aleksandra Divac Rankov; Mila Ljujic; Branimir Nestorovic; Dragica Radojkovic
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-06       Impact factor: 1.349

8.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Authors:  Patrick R Sosnay; Karen R Siklosi; Fredrick Van Goor; Kyle Kaniecki; Haihui Yu; Neeraj Sharma; Anabela S Ramalho; Margarida D Amaral; Ruslan Dorfman; Julian Zielenski; David L Masica; Rachel Karchin; Linda Millen; Philip J Thomas; George P Patrinos; Mary Corey; Michelle H Lewis; Johanna M Rommens; Carlo Castellani; Christopher M Penland; Garry R Cutting
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

9.  Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.

Authors:  S Vamsee Raju; Jody H Tate; Sandra K G Peacock; Ping Fang; Robert A Oster; Mark T Dransfield; Steven M Rowe
Journal:  Respir Res       Date:  2014-02-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.